CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
We compare index funds and target date funds for retirement to help you decide based on time horizon, risk tolerance, costs, and tax considerations.
26,044 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Bitcoin sits roughly 43% below its all-time high as macro headwinds and fund outflows weigh on sentiment. This report...
SpaceX is courting attention ahead of a potential Nasdaq debut. Some ETFs offer pre-IPO exposure via SPVs, but the st...
Webull rolled out a March 2026 cash-bonuses program, offering tiered deposit matches and a first-transfer reimburseme...
A high-profile moment can ripple into personal finances. This piece examines the Tyson Paris Fury Face backlash, what...
In a real-time test, we asked AI to pick the best crypto among Bitcoin, XRP, and Solana. The AI ranked Solana first, ...
When the world's biggest ethereum treasury buys the dip, it grabs headlines—and raises questions for everyday investo...
Roundhill unveiled plans for a suite of ETFs that would track prediction-market odds on the 2028 U.S. election, signa...
Harvey, an AI-driven legal tech startup, has surged to an $11 billion valuation after attracting OpenAI backing. The ...
A high-profile health hiccup on opening night offers a blunt lesson in personal finance for fans and performers. Lear...
In a dramatic Q1, a bold Bitcoin-focused strategy posts a $12.5 billion loss. This article explains what happened, wh...
Israeli Prime Minister Benjamin Netanyahu signaled that the Iran conflict is far from over because enriched uranium r...